CIRCUMVENTION OF MULTIDRUG-RESISTANCE WITH ANTI-P-GLYCOPROTEIN ANTIBODIES - CLINICAL POTENTIAL OR EXPERIMENTAL ARTIFACT

被引：8
作者：
BECK, WT
机构：
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 1995年 / 87卷 / 02期
关键词：
D O I：
10.1093/jnci/87.2.73
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：73 / 75
页数：3
相关论文
共 37 条
[1]   PHASE-I TRIAL OF DOXORUBICIN WITH CYCLOSPORINE AS A MODULATOR OF MULTIDRUG-RESISTANCE [J].
BARTLETT, NL ;
LUM, BL ;
FISHER, GA ;
BROPHY, NA ;
EHSAN, MN ;
HALSEY, J ;
SIKIC, BI .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :835-842
[2]  
BECK WT, 1990, B CANCER, V77, P1131
[3]   DO ANTI-P-GLYCOPROTEIN ANTIBODIES HAVE A FUTURE IN THE CIRCUMVENTION OF MULTIDRUG RESISTANCE [J].
BECK, WT .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (19) :1364-1366
[4]  
BECK WT, 1991, MOL CLIN ADV ANTICAN, P151
[5]  
BRUGGEMANN EP, 1990, J BIOL CHEM, V265, P4172
[6]  
BRUGGEMANN EP, 1989, J BIOL CHEM, V264, P15483
[7]  
CHAUDHARY PM, 1992, BLOOD, V80, P2735
[8]  
CORRIAS MV, 1992, ANTICANCER RES, V12, P1431
[9]  
DEVITA VT, 1989, CANC PRINCIPLES PRAC, V1, P278
[10]  
EFFERTH T, 1992, MED ONCOL TUMOR PHAR, V9, P11
1234